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Two GTP-binding proteins serving asthe specific substrate of islet-activating protein (IAP), pertussis toxin, were purified 
from human platelet membranes as heterotrimers with an c&-subunit structure. The a of the major IAP substrate had 
a molecular mass of 40 kDa and differed from that of Gil or G. previously purified from brain membranes. The partial 
amino acid sequences of the 40 kDa a completely matched with the sequences which were deduced from the nucleotide 
sequences of the human Gi2 a gene. On the other hand, the a of the minor IAP substrate purified from human platelets 
was about 41 kDa and cross-reacted with an antibody raised against a of brain Gi i (Gi i a). These results indicate that 
the major IAP substrate present in human platelet membranes i a product of the G1r a gene. 
GTP-binding protein; Islet-activating protein; Pertussis toxin; (Human platelet) 
1. INTRODUCTION 
In a variety of vertebrate cells, GTP-binding 
proteins function as transducers that carry signals 
from activated receptors to effecters such as en- 
zymes or ion channels [I]. GTP-binding proteins 
have been purified from several types of cell mem- 
branes as heterotrimers with an &-subunit struc- 
ture. Their a-subunits which bind GTP or GDP are 
unique, while the fly-subunits are similar if not 
identical to each other. Molecular cloning of the LY- 
subunit genes [2] and cDNAs [3-91 has recently 
been achieved. The data indicate the existence of at 
least four genes for the a-subunits (Gi i (Y, Gi 2 (Y, 
Gi 3 LY and G, cu) of GTP-binding proteins serving 
as the substrate of islet-activating protein (IAP), 
pertussis toxin, besides two transducin a-subunits 
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(Gt r ,Z and Gt 2 cu) [5-81. More recently, three IAP 
substrates have been purified from brain mem- 
branes [ 10,l l] and compared with predicted amino 
acid sequences from the a-subunit genes and 
cDNAs [ 121. 
Several lines of evidence have suggested that a 
GTP-binding protein(s) is involved in receptor- 
coupled phosphoinositide hydrolysis (i.e., phos- 
pholipase C activation) in many types of cells 
[13-161 including human platelets [17,18]. Phos- 
phatidic acid formation and Ca*+ release 
stimulated by thrombin were inhibited in platelets 
which had been treated with IAP [17]. These 
reports suggest that he GTP-binding protein 
associated with phospholipase C activation may be 
sensitive to IAP in platelets. However, such a GTP- 
binding protein present in platelet membranes re- 
mains to be isolated and characterized. Here, we 
report the purification and identification of human 
platelet GTP-binding proteins serving as the 
specific substrate of IAP. 
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2. MATERIALS AND METHODS 
2.1. Purification of IAP substrates from human platelet 
membranes 
The procedures employed to purify the IAP substrates from 
human platelet membranes are based on the methods developed 
to purify Gi and G, from rat [lo] or porcine brain [ll] with 
slight modification. After five chromatography steps with Q- 
Sepharose, heparinSepharose, Sephacryl S-3OO(HR), phenyl- 
Sepharose and DEAE-Toyopearl 650(S), an aliquot (10 nmol) 
of the fractions containing IAP substrate activity was diluted 
with 4 vols Tris-HCl (pH 8.0)/0.1 mM EDTA/l mM dithio- 
threitol/lOO mM NaCl (TEDN) containing 0.7% 3-[(3-chol- 
amidopropyl)dimethylammonio]-1-propanesulfonate (Chaps) 
and then applied to a column of hydroxyapatite (HCA-100s; 
1 x 10 cm) which had been equilibrated with the above solution. 
The column was washed and eluted at a flow rate of 1 ml/min 
with the following series of potassium phosphate gradients using 
a Pharmacia FPLC system; 0 mM for 10 min; O-40 mM over 
30 min; 40-200 mM over 3 min; 200 mM over 7 min. The 
eluate was collected in fractions of 1 ml. This chromatography 
resulted in the separation of two peaks of the IAP-substrate ac- 
tivity (fig.1); the first minor peak (II, fractions 22-24 min) and 
the second major peak (I, fractions 26-28 min). Thus, two IAP 
substrates were purified to almost homogeneity from the human 
platelet membranes. The polypeptide composition of the 
purified proteins was analyzed by SDS-polyacrylamide gel elec- 
trophoresis (SDS-PAGE) and is shown in fig.lA. The radio- 
labeled bands of IAP-catalyzed [‘*P]ADP-ribosylation of the 
purified proteins are also illustrated in fig.lB. 
2.2. Assays of activities and immunoblot procedures 
The IAP substrate protein was identified by its abilities to be 
[“P]ADP-ribosylated in the presence of IAP and [u-“P]NAD 
as in [lO,ll]. Electrophoresis of polypeptides through SDS- 
polyacrylamide gels and the treatment of the samples with N- 
ethylmaleimide were as described in [ 191. lmmunoblot analysis 
was performed essentially as in [ll]. Antibodies utilized were: 
affinity-purified rabbit polyclonal antibodies prepared against 
the (Y of Gt I (ant&i), the (Y of G, (anti-o3s) and the& of Gi L 
and G, (anti-B) purified from rat brain, which specifically 
reacted with the ~41, as9 and ,835/36, respectively, as described 
[l I]; a rabbit polyclonal antibody (anti-o) prepared against he 
mixture of porcine brain ~~41, osg and ada. The latter antibody 
Fig.1. HCA-100(S) chromatography of IAP substrates from human platelet membranes. IAP substrate-rich fractions were applied to 
HCA-100(S) and eluted as described in section 2. Aliquots (5 ~1) of the fractions (I; fractions 26-28 min; II, fractions 22-24 min) were 
assayed for IAP-substrate (stippled areas) activity. (A) SDS-PAGE of fractions I and II. Proteins were subjected to SDS-polyacrylamide 
gel (10%) electrophoresis and stained with silver. Lanes: 1, peak I; 2, peak II; 3, molecular mass standards (Bio-Rad). The markers were 
phosphorylase b(92.5 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), soybean trypsin in- 
hibitor (21.5 kDa) and lysozyme (14.4 kDa). (B) [“P]ADP-ribosylated cr. Lanes: 1, peak I; 2, peak II. 
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reacted strongly with brain LYJ~, and poorly with cy4r and a;ls (see 
fig.3). 
2.3. Tryptic digestion of human platelet 40 kDa wsubunit and 
sequence analysis of the tryptic peptides 
Resolution of the major IAP substrate (see fig.1, peak I) to 
the 40 kDa LY and the ,& was performed by phenyl-Sepharose 
chromatography in the presence of A13+, Mg’+ and F- as in 
1201. The sample containing approx. 2 nmol of the purified 
40 kDa LY was heated at 70°C for 5 min and digested at 37°C for 
20 h with tosylphenylalanyl chloromethyl ketone-treated tryp- 
sin (TPCK-trypsin) at a protein/trypsin ratio of 50 (w/w). After 
tryptic digestion, the sample was applied to a column of 
PepRPC HR5/5 which had been equilibrated with 0.1% tri- 
fluoroacetic acid containing 5% acetonitrile. The tryptic pep- 
tides were eluted with a linear gradient of 5-40% acetonitrile at 
a flow rate of 0.7 ml/min using a Pharmacia FPLC system. The 
absorbance at 214 nm of the eluate was monitored. The eluted 
fractions were subjected to amino acid sequence analysis with an 
applied Biosystems model 477A sequencer. 
3. RESULTS AND DISCUSSION 
Platelet responses to agonists are believed to be 
mediated by phospholipase C activation. Recently, 
substantial evidence has been accumulated which 
indicates that phospholipase C activity in platelet is 
regulated via a GTP-binding protein, G, 
[17,22,23]. This protein is believed to be IAP- 
sensitive. However, at present, it remains unclear 
whether regulation of phospholipase C involves a 
novel GTP-binding protein, or a new role for a 
previously characterized IAP-sensitive protein. 
GTP-binding proteins in platelet membranes were 
detected by IAP-catalyzed ADP-ribosylation or 
immunoblot analysis, but none have been isolated. 
Thus, we attempted to purify and identify GTP- 
binding protein(s) of human platelet membranes. 
Proteins obtained by solubilization of human 
platelet membranes with sodium cholate were ap- 
plied to columns of Q-Sepharose, heparin- 
Sepharose, Sephacryl S300(HR), phenyl-sepha- 
rose and DEAE-Toyopearl 650(S), successively. 
After these five chromatography steps, IAP 
substrate-rich fractions were further purified on an 
HCA-100s column (fig.1). Two peaks of the IAP 
substrate activity eluting from the column had 
GTPyS-binding activities. The polypeptide com- 
positions of the major fractions analyzed by SDS- 
PAGE are also shown in fig.1, together with the 
autoradiogram of the same fractions radiolabeled 
by IAP and [32P]NAD. These results indicate that 
there are two kinds of CY that are the substrates of 
IAP-catalyzed ADP-ribosylation in human platelet 
membranes. The molecular mass of the (Y of the 
main substrate (G(1)) was 40 kDa on SDS gels 
(fig.2). On the other hand, the LY of the minor IAP- 
substrate (G(I1)) had the same molecular mass as 
that of Gi 1 (a4&) on SDS gels (fig.2). &Subunits 
of 35 and 36 kDa were also observed. It is notewor- 
thy that the content of 36 kDafi is almost equal to 
that of 35 kDa in human platelet membranes while 
Gi 1 (a41pyh Gi 2 k~4c&) or Go (c~35&) has the 
main p with a molecular mass of 36 kDa (fig.2). 
Furt,hermore, immunochemical cross-reactivities 
were examined for a of G(I), cy of G(II), Gi I a and 
G, cr. Gi 1 cy and G, (Y resolved from purified rat 
brain Gi I and G, were used to prepare affinity- 
purified antibodies for immunoblot analysis [ 111. 
As shown in fig.3A, an antibody raised against rat 
brain Gi 1 a (anti-cuhr) eacted with porcine brain 
Gi I a, but not with porcine brain G, cy or cy of 
platelet G(1). On the other hand, the antibody rais- 
ed against rat brain G, cy (anti-& reacted with 
porcine brain G, cr, but not with porcine brain Gi 1 
cy, Gi 2 a or (Y of platelet G(1) (fig.3B). Thus, 
neither anti-cud1 nor -a99 cross-reacted with CY of 
platelet G(I), suggesting that G(1) was immuno- 
chemically different from brain Gi I or G,. Anti- 
~~41 cross-reacted with (Y of G(I1). However, the 
homology of the amino acid sequences between 
Gi I a and Gi 3 cy is more than 90% and it is difficult 
to identify G(I1) as Gr 1. The antibody raised 
against the identical or highly homologous se- 
quences (anti-a) reacted with these five (Y subunits 
(fig.3C). The fly-subunits resolved from rat brain 
Gi I and G, were also used to prepare an affinity- 
purified antibody. The antibody thus obtained 
(anti-p) reacted with all the&subunits of Gi I, Gi 2, 
G,, G(1) and G(II), suggesting that thep of the five 
IAP substrates are the same polypeptide or at least 
share (a) common antigenic determinant(s) 
(fig.3D). 
For amino acid sequence analysis, platelet G(1) 
was resolved into the (Y and fly as described above. 
The CY was digested with TPCK-trypsin, and the 
cleavage products were separated by reverse-phase 
high-performance liquid chromatography (fig.4). 
Five fractions (l-5) corresponding to the absor- 
bance peaks were collected and subjected to amino 
acid sequence analysis. Fractions 3-5 contained a 
single peptide, while fractions 1 and 2 were mix- 
tures of two and three peptides, respectively. The 
sequences determined were as follows: l-l, EIYT- 
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Fig.2. SDS-polyacrylamide gel electrophoresis and IAP-catalyzed ADP-ribosylation of IAP substrates purified from human platelet 
membranes. Proteins (1 pg) were subjected to SDS-polyacrylamide gel (10%) electrophoresis. The gel was then stained with Coomassie 
blue (A) or silver(B). Proteins which had been [32P]ADP-ribosylated by IAP and [32P]NAD were also subjected to SDS-PAGE followed 
by silver stain ((C), lower) and autoradiography ((C), upper). Lanes: 1, porcine brain Gil; 2, porcine brain G,; 3, porcine brain Giz; 4, 
human platelet G(I); 5, human platelet G(I1). 
Fig.3. Cross-reaction of human platelet IAP substrates with affinity-purified antibodies pecific for the rat brain IAP substrates. Two 
IAP substrates (1 ,xg) purified from human platelet membranes were subjected to SDS-polyacrylamide gel (10%) electrophoresis and 
analyzed for immunoblot as described in section 2. Lanes: 1, Gil (~y41p 7); 2, G, (~3gp y); 3, Giz (cy40,8 y); 4, human platelet G(1); 5, 
human platelet G(I1). (A) Anti-rat ~y4r antibody, (B) anti-rat (~39 antibody, (C) anti-porcine cy antibody, (D) anti-rat ,8 antibody. 
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Fig.4. Reverse-phase FLPC analysis of tryptic peptides from 
human platelet G(I). Tryptic peptides of G(1) were applied to a 
PepPRC HR5/5 column and eluted as described in section 2. 
Five peaks (l-5) were subjected to amino acid sequence analysis. 
HFTXAT; l-2, LFDSIXNNK; 2-1, IAQSDYIPT- 
QQDVLR; 2-2, LLLLGAGESGK; 2-3, DXGLF; 
3, LWADHGVQAXFGR; 4, EYQLNDSAAYYL- 
NDLER; 5, ITHSPLTIXFPEYTGANK. Assign- 
ment of the peptides in fraction l-5 was based on 
the predicted amino acid sequences from the 
known GTP-binding protein a-subunit genes and 
cDNAs. The partial amino acid sequences of LY of 
G(1) were completely identical with the predicted 
sequences of the human Gi 2 (Y gene [2], thereby 
suggesting that the major pertussis toxin substrate 
in human platelet membranes is Gi 2, which has 
been isolated from porcine brain [ 11,121. 
In this report, we have purified the main IAP 
substrate, referred to as G(I), from human platelet 
membranes. The physiological role of G(1) is un- 
known at present. Since hormonal inhibition of 
adenylate cyclase activity may be mediated at least 
in part by the release of fly-subunits [21], G(1) is 
also thought to have a function, as have Gt I and 
G,, in receptor-linked inhibition of the cyclase. 
Nevertheless, it is tempting to speculate that LY of 
G(1) is capable of interacting with an enzyme 
system other than adenylate cyclase, e.g. phospho- 
lipase C, since recent studies have revealed that 
prior exposure of platelet o IAP attenuates the cell 
responses to receptor stimulation in a CAMP- 
independent manner [ 17,181. 
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